Cagrilintide / Semaglutide 2.5mg/2.5mg/3mL

What is Cagrilintide / Semaglutide?

This innovative combination formulation brings together Cagrilintide, a long-acting amylin analogue, and Semaglutide, the well-researched GLP-1 receptor agonist. This pairing mirrors the investigational approach being explored in landmark clinical trials studying dual-hormone strategies for metabolic research.

By targeting both amylin and GLP-1 receptors simultaneously, researchers are exploring whether this combination may offer a more comprehensive approach to appetite and metabolic regulation than either compound alone.

Mechanism of Action

This dual-compound formulation is being studied for its potential to influence:

• Amylin receptor activation (Cagrilintide) — supports satiety signaling through pathways distinct from GLP-1
• GLP-1 receptor activation (Semaglutide) — promotes satiety, slows gastric emptying, and supports insulin response
• Complementary appetite suppression — dual-pathway approach to food intake regulation
• Metabolic balance — combined influence on glucose metabolism and energy homeostasis

Areas of Research

Current studies are evaluating this combination's potential role in:

• Weight management and obesity research
• Dual-hormone metabolic therapy
• Appetite and food intake regulation
• Glucose metabolism and insulin sensitivity

Research Use Only

This product is intended for laboratory research purposes only. It is not intended for human consumption, medical use, diagnosis, cure, mitigation, treatment, or prevention of any disease. This product has not been evaluated by the U.S. Food and Drug Administration (FDA). Purchasers are responsible for compliance with all applicable laws and regulations regarding the use and handling of research materials.